Table 2 Selected characteristics of studies investigating Anda‐TB (Anda Biologicals, Strasbourg, France) for the diagnosis of extrapulmonary tuberculosis.
| Reference | Data collection | Verification | Reference standard | Disease site | Country | Comparison group | Ig class | No. of participants* | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|---|---|---|---|
| Alifano (1998, a)41 | Retrospective | Differential | Culture and/ or histology | Multiple | Italy | Mixed disease | IgG | 42/44 | 0.74 (0.58 to 0.86) | 0.93 (0.81 to 0.99) |
| Alifano (1998, b)41 | Retrospective | Differential | Culture and/ or histology | Multiple | Italy | Mixed disease | IgA | 42/44 | 0.69 (0.53 to 0.82) | 0.89 (0.75 to 0.96) |
| Banerjee (2003, a)42 | Retrospective | NR | Histology | Lymph node | India | Healthy | IgG | 30/32 | 0.43 (0.25 to 0.63) | 0.59 (0.41 to 0.76) |
| Caminero (1993)43 | Prospective | Complete | Culture and/ or histology | Pleura | Spain | Pleural TB suspects | IgG | 30/48 | 0.53 (0.34 to 0.72) | 1.00 (0.93 to 1.00) |
| Caminero (1994)44 | Prospective | Differential | Culture and/ or histology | Multiple | Canary Islands | Non‐TB respiratory | IgG | 56/31 | 0.32 (0.20 to 0.46) | 0.94 (0.79 to 0.99) |
| Gevaudan (1992, a)45 | Retrospective | Differential | Culture and/ or histology | Lymph node | France | Mixed disease | IgG | 26/194 | 1.00 (0.87 to 1.00) | 0.76 (0.69 to 0.82) |
| Gevaudan (1992, b)45 | Retrospective | Differential | Culture and/ or histology | Lymph node | France | Mixed disease | IgM | 26/194 | 0.23 (0.09 to 0.44) | 0.95 (0.91 to 0.98) |
| Gevaudan (1992, c)45 | Retrospective | Differential | Culture | Disseminated/miliary (primary) | France | Mixed disease | IgG | 56/194 | 0.95 (0.85 to 0.99) | 0.76 (0.69 to 0.82) |
| Gevaudan (1992, d)45 | Retrospective | Differential | Culture | Disseminated/miliary (primary) | France | Mixed disease | IgM | 56/194 | 0.32 (0.20 to 0.46) | 0.95 (0.91 to 0.98) |
| Gevaudan (1992, e)45 | Retrospective | Differential | Culture | Disseminated/miliary (post‐primary) | France | Mixed disease | IgG | 25/194 | 1.00 (0.86 to 1.00) | 0.76 (0.69 to 0.82) |
| Gevaudan (1992, f)45 | Retrospective | Differential | Culture | Disseminated/miliary (post‐primary) | France | Mixed disease | IgM | 25/194 | 0.00 (0.00 to 0.14) | 0.95 (0.91 to 0.98) |
| Gevaudan (1992, g)45 | Retrospective | Differential | Culture | Genitourinary | France | Mixed disease | IgG | 34/194 | 1.00 (0.90 to 1.00) | 0.76 (0.69 to 0.82) |
| Gevaudan (1992, h)45 | Retrospective | Differential | Culture | Genitourinary | France | Mixed disease | IgM | 34/194 | 0.00 (0.00 to 0.10) | 0.95 (0.91 to 0.98) |
| Kunter (2003, a)46 | Prospective | Differential | Culture | Pleura | Turkey | Non‐TB respiratory | IgG | 88/37 | 0.26 (0.17 to 0.37) | 0.86 (0.71 to 0.96) |
| Kunter (2003, b)46 | Prospective | Differential | Culture | Pleura | Turkey | Non‐TB respiratory | IgM | 88/37 | 0.48 (0.37 to 0.59) | 0.92 (0.78 to 0.98) |
| Kunter (2003, c)46 | Prospective | Differential | Culture | Pleura | Turkey | Non‐TB respiratory | IgG and IgM | 88/37 | 0.59 (0.48 to 0.70) | 0.81 (0.65 to 0.92) |
| Luh (1996)47 | Prospective | NR | Culture | Multiple | Taiwan | Mixed disease | IgG | 35/224 | 0.63 (0.45 to 0.79) | 0.92 (0.88 to 0.96) |
TB, tuberculosis; Ig, immunoglobulin; NR, not reported.
The treatment status of cases was not reported for reference 45. For all other studies, patients were either not on treatment or on treatment for <14 days at the time serum was obtained.
*Number of participants with tuberculosis/without tuberculosis.